NanoVation Therapeutics Partners with Novo Nordisk
VANCOUVER, British Columbia -- NanoVation Therapeutics, an innovative company specializing in nucleic acid delivery, has announced a major partnership with Novo Nordisk. This collaboration aims to develop revolutionary genetic medicines that focus on treating cardiometabolic and rare diseases. By combining NanoVation's cutting-edge long-circulating lipid nanoparticle (lcLNP™) technology with Novo Nordisk's extensive experience in medical research and clinical development, this alliance is set to make waves in the field.
Details of the Collaboration and Its Objectives
Through this agreement, both companies will work together on two main projects focused on creating base-editing therapies for certain rare genetic disorders. Additionally, they plan to investigate up to five other potential therapeutic targets in the areas of cardiometabolic and rare diseases. Novo Nordisk will gain exclusive global rights to use NanoVation’s LNP technology specifically for these two programs. Furthermore, NanoVation will receive vital research funding and has the chance to earn up to US$600 million through initial cash payments, achievement milestones, and tiered royalties from any future product sales.
Insights from Leadership on the Partnership
"We founded NanoVation to help our partners tackle the challenges associated with traditional nucleic acid delivery systems," said Dominik Witzigmann, PhD, co-founder and CEO of NanoVation Therapeutics. “This partnership with Novo Nordisk showcases the capabilities of our LNP technologies and their potential to advance the next generation of transformative genetic therapies. We’re excited about collaborating with Novo Nordisk’s talented team.”
Karina Thorn, PhD, Corporate Vice President and Head of Research for Global Nucleic Acid Therapies at Novo Nordisk, added, "Every genetic treatment necessitates careful thought regarding its components and delivery methods, which require innovative solutions. We look forward to our partnership with NanoVation, as their unique delivery technologies could boost our efforts to advance genetic medicine candidates with the potential to treat diseases."
The Significance of NanoVation's Technology
Co-founder Pieter Cullis, PhD, a recognized leader in lipid nanoparticle (LNP) technology, highlighted the significance of this partnership. "We're at a pivotal point in genetic medicine, and this collaboration underscores NanoVation’s role as a key innovator in nucleic acid delivery," Cullis noted. "By using our skills in delivering therapies outside of the liver alongside Novo Nordisk's expertise in cardiometabolic and rare diseases, we have the potential to develop groundbreaking treatment options."
Looking Ahead: The Future of Genetic Medicine
NanoVation is rapidly growing its library of novel lipids and LNP formulations. The company teams up with industry leaders from the conceptual stage to the lead development phases, providing specialized solutions for effective nucleic acid delivery. Preliminary studies suggest that NanoVation’s lcLNP technology can deliver nucleic acids to a wide variety of cell types beyond the liver, showing significant improvements in terms of potency, safety, and stability when compared to traditional delivery methods. They also maintain a comprehensive Intellectual Property (IP) portfolio to support genetic medicine development, covering everything from lipid design to RNA modifications and LNP formulations.
About NanoVation Therapeutics
NanoVation Therapeutics is an innovator focused on designing and developing lipid nanoparticles (LNPs) for nucleic acid delivery. The company aims to overcome the limitations of current nucleic acid delivery methods, particularly for targeting tissues outside the liver. Their leading technology is the proprietary long-circulating LNP (lcLNP™) platform, which facilitates the functional delivery of nucleic acids to non-liver cells. Preliminary studies show that this technology has an improved therapeutic index, and NanoVation is committed to partnering with advanced pharmaceutical and biotech firms to create genetic medicines for previously untreatable conditions.
Frequently Asked Questions
What is the purpose of the partnership between NanoVation and Novo Nordisk?
This partnership intends to develop innovative genetic medicines that focus on cardiometabolic and rare diseases using advanced LNP technology.
What technology does NanoVation Therapeutics utilize?
NanoVation employs proprietary long-circulating lipid nanoparticle (lcLNP™) technology to enable the delivery of nucleic acids to cells outside of the liver.
What are the financial details concerning this partnership?
NanoVation is expected to secure research funding and stands to earn up to about US$600 million in upfront cash and milestone payments.
Who are the key individuals at NanoVation Therapeutics?
Key individuals include Dominik Witzigmann, CEO, and Pieter Cullis, co-founder and Board Chair, both of whom contribute significantly to the field of nucleic acid delivery.
How does NanoVation's technology differ from conventional methods?
NanoVation's lcLNP technology provides improved potency, safety, and stability, allowing for effective delivery to a broader range of cell types than traditional systems.
